Skip to main content

Table 2 Treatment patterns among Medicare-eligible Stage IV ER + breast cancer patients who did not receive HER2 targeted agents

From: Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

Characteristic Study cohort
With > 2 months of follow-up to allow for treatment  
  N 285
  % 87.7%
  Receiving surgery within 4 months of diagnosis  
   N 110
   % 38.60%
  Receiving radiation within 4 months of diagnosis  
   N 91
   % 31.93%
  Receiving any medication  
   N 212
   % 74.4%
   Type of treatment received (at any time post-index)  
    Chemotherapy alone 15.1%
    Aromatase Inhibitors (AI) therapy  
     Anastrazole monotherapy 11.8%
     Letrozole monotherapy 9.4%
     Exmenestane monotherapy 1.4%
     Multiple AI therapies 2.4%
    Non-AI therapy  
     Fulvestrant monotherapy 4.2%
     Tamoxifen monotherapy 1.9%
     Toremifene monotherapy 0.0%
     Megestrol monotherapy 0.9%
     Multiple non-AI therapies 0.5%
    Chemotherapy combined with AI therapy 11.8%
    Chemotherapy combined with non-AI therapy 15.1%
    AI therapy combined with non-AI therapy 10.4%
    Chemotherapy combined with AI and non-AI therapy 15.1%
   Duration of any treatment (months)  
    Mean ± SD 12.9 ± 9.1
    Median 11.0
   Duration of AI treatment (months), among those with any AI use  
    Mean ± SD 11.0 ± 8.1
    Median 9.5
   Duration of non-AI treatment (months), among those with any non-AI use
    Mean ± SD 5.6 ± 5.4
    Median 4.0
   Duration of chemo treatment (months), among those with any chemo use
    Mean ± SD 8.5 ± 7.2
    Median 6.0
\